ISRN Pharmacology最新文献_第6页

Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects. 在健康男性受试者中，单次给药咖啡灌肠与口服咖啡后咖啡因的药代动力学

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-03-04 DOI: 10.1155/2013/147238

Supanimit Teekachunhatean, Nisanuch Tosri, Noppamas Rojanasthien, Somdet Srichairatanakool, Chaichan Sangdee

{"title":"Pharmacokinetics of Caffeine following a Single Administration of Coffee Enema versus Oral Coffee Consumption in Healthy Male Subjects.","authors":"Supanimit Teekachunhatean, Nisanuch Tosri, Noppamas Rojanasthien, Somdet Srichairatanakool, Chaichan Sangdee","doi":"10.1155/2013/147238","DOIUrl":"https://doi.org/10.1155/2013/147238","url":null,"abstract":"The objective of this study was to determine the pharmacokinetics of caffeine after single administration of a coffee enema versus coffee consumed orally in healthy male subjects. The study design was an open-label, randomized two-phase crossover study. Eleven healthy subjects were randomly assigned either to receive 500 mL of coffee enema for 10 minutes or to consume 180 mL of ready-to-drink coffee beverage. After a washout period of at least 10 days, all the subjects were switched to receive the alternate coffee procedure. Blood samples were collected immediately before and at specific time points until 12 hours after coffee administration in each phase. The mean caffeine content in both the coffee solution prepared for the coffee enema and the ready-to-drink coffee beverage was not statistically different. The C max and AUC of caffeine obtained from the coffee enema were about 3.5 times significantly less than those of the coffee consumed orally, despite having slightly but statistically faster T max. The t 1/2 of caffeine obtained following both coffee procedures did not statistically differ. In summary, the relative bioavailability of caffeine obtained from the coffee enema was about 3.5 times significantly less than those of the coffee consumed orally.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":" ","pages":"147238"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/147238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40227423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 54

Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice. 药物基因组学翻译在临床实践中的科学挑战和实施障碍。

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-02-28 DOI: 10.1155/2013/641089

Y W Francis Lam

{"title":"Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.","authors":"Y W Francis Lam","doi":"10.1155/2013/641089","DOIUrl":"https://doi.org/10.1155/2013/641089","url":null,"abstract":"The mapping of the human genome and subsequent advancements in genetic technology had provided clinicians and scientists an understanding of the genetic basis of altered drug pharmacokinetics and pharmacodynamics, as well as some examples of applying genomic data in clinical practice. This has raised the public expectation that predicting patients' responses to drug therapy is now possible in every therapeutic area, and personalized drug therapy would come sooner than later. However, debate continues among most stakeholders involved in drug development and clinical decision-making on whether pharmacogenomic biomarkers should be used in patient assessment, as well as when and in whom to use the biomarker-based diagnostic tests. Currently, most would agree that achieving the goal of personalized therapy remains years, if not decades, away. Realistic application of genomic findings and technologies in clinical practice and drug development require addressing multiple logistics and challenges that go beyond discovery of gene variants and/or completion of prospective controlled clinical trials. The goal of personalized medicine can only be achieved when all stakeholders in the field work together, with willingness to accept occasional paradigm change in their current approach.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":" ","pages":"641089"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/641089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40227425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 52

Inhibitory Effect of Aqueous Extract of Stem Bark of Cissus populnea on Ferrous Sulphate- and Sodium Nitroprusside-Induced Oxidative Stress in Rat's Testes In Vitro. 山竹茎皮水提物对硫酸亚铁和硝普钠诱导大鼠睾丸氧化应激的抑制作用。

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-01-21 DOI: 10.1155/2013/130989

Seun F Akomolafe, Ganiyu Oboh, Afolabi A Akindahunsi, Ayodele J Akinyemi, Oluwatosin G Tade

{"title":"Inhibitory Effect of Aqueous Extract of Stem Bark of Cissus populnea on Ferrous Sulphate- and Sodium Nitroprusside-Induced Oxidative Stress in Rat's Testes In Vitro.","authors":"Seun F Akomolafe, Ganiyu Oboh, Afolabi A Akindahunsi, Ayodele J Akinyemi, Oluwatosin G Tade","doi":"10.1155/2013/130989","DOIUrl":"https://doi.org/10.1155/2013/130989","url":null,"abstract":"Cissus populnea are plants associated with a myriad of medicinal uses in different parts of the world and are good sources of carotenoids, triterpenoids, and ascorbic acid. The antioxidant properties and inhibitory effect of water extractible phytochemicals from stem bark of C. populnea on FeSO(4) and sodium nitroprusside- (SNP-) induced lipid peroxidation in rat testes were investigated in vitro. The results revealed that the extract was able to scavenge DPPH radical, chelate Fe(2+) and also had a high reducing power. Furthermore, the incubation of the testes tissue homogenate in the presence of FeSO(4) and SNP, respectively, caused a significant increase in the malondialdehyde (MDA) contents of the testes. However, the aqueous extract of the stem bark of C. populnea caused a significant decrease in the MDA contents of both Fe(2+) (EC(50) = 0.027 mg/mL) and SNP- (EC(50) = 0.22 mg/mL) induced lipid peroxidation in the rat testes homogenates in a dose-dependent manner. The water extractible phytochemicals from C. populnea protect the testes from oxidative stress and this could be attributed to their high antioxidant activity: DPPH-scavenging ability, Fe(2+)-chelating and -reducing power. Therefore, oxidatively stress in testes could be potentially managed/prevented by this plant.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2013 ","pages":"130989"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/130989","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31231711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Bioequivalence Study of Pantoprazole Sodium-HPBCD and Conventional Pantoprazole Sodium Enteric-Coated Tablet Formulations. 泮托拉唑钠- hpbcd与常规泮托拉唑钠肠溶片的生物等效性研究。

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-02-07 DOI: 10.1155/2013/347457

Sandesh P Kamdi, Prashant J Palkar

{"title":"Bioequivalence Study of Pantoprazole Sodium-HPBCD and Conventional Pantoprazole Sodium Enteric-Coated Tablet Formulations.","authors":"Sandesh P Kamdi, Prashant J Palkar","doi":"10.1155/2013/347457","DOIUrl":"https://doi.org/10.1155/2013/347457","url":null,"abstract":"The objective of this study was to investigate the bioequivalence of two formulations of 40 mg pantoprazole sodium enteric-coated tablets: Tripepsa as the test and Pantocid as the reference. The two products were administered as a single oral dose according to a randomized two-phase crossover with a 1-month washout period in 25 healthy Indian volunteers. After drug administration, serial blood samples were collected over a period of 30 hours. Plasma pantoprazole concentrations were measured by high-performance liquid chromatography with UV detection. Pharmacokinetic parameters were analyzed based on noncompartmental analysis. The logarithmically transformed data of AUC0-∞ and Cmax were analyzed for 90% confidence intervals (CI) using ANOVA. The mean (90% CI) values for the ratio of AUC0-∞ and Cmax values of the test product over those of the reference product were 90.21 (83.69-97.24) and 108.68 (100.21-117.86), respectively (within the bioequivalence range of 80-125%). On the basis of pharmacokinetic parameters including AUC0-∞ , AUC0-t , and Cmax values, both the formulations were bioequivalent.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2013 ","pages":"347457"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/347457","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31296158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients. 瑞舒伐他汀、阿托伐他汀和普伐他汀治疗血脂异常糖尿病的疗效和安全性比较。

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-02-10 DOI: 10.1155/2013/146579

Lolwa Barakat, Amin Jayyousi, Abdulbari Bener, Bilal Zuby, Mahmoud Zirie

{"title":"Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients.","authors":"Lolwa Barakat, Amin Jayyousi, Abdulbari Bener, Bilal Zuby, Mahmoud Zirie","doi":"10.1155/2013/146579","DOIUrl":"https://doi.org/10.1155/2013/146579","url":null,"abstract":"Objectives. To investigate the efficacy and the safety of the three most commonly prescribed statins (rosuvastatin, atorvastatin, and pravastatin) for managing dyslipidemia among diabetic patients in Qatar. Subjects and Methods. This retrospective observational population-based study included 350 consecutive diabetes patients who were diagnosed with dyslipidemia and prescribed any of the indicated statins between September 2005 and September 2009. Data was collected by review of the Pharmacy Database, the Electronic Medical Records Database (EMR viewer), and the Patient's Medical Records. Comparisons of lipid profile measurements at baseline and at first- and second-year intervals were taken. Results. Rosuvastatin (10 mg) was the most effective at reducing LDL-C (29.03%). Atorvastatin reduced LDL-C the most at a dose of 40 mg (22.8%), and pravastatin reduced LDL-C the most at a dose of 20 mg (20.3%). All three statins were safe in relation to muscular and hepatic functions. In relation to renal function, atorvastatin was the safest statin as it resulted in the least number of patients at the end of 2 years of treatment with the new onset of microalbuminuria (10.9%) followed by rosuvastatin (14.3%) and then pravastatin (26.6%). Conclusion. In the Qatari context, the most effective statin at reducing LDL-C was rosuvastatin 10 mg. Atorvastatin was the safest statin in relation to renal function. Future large-scale prospective studies are needed to confirm these results.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2013 ","pages":"146579"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/146579","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31293892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 43

Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. 非典型抗精神病药物对细胞色素p450体外抑制作用的比较。

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-02-13 DOI: 10.1155/2013/792456

Guillermo Gervasini, Maria J Caballero, Juan A Carrillo, Julio Benitez

{"title":"Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs.","authors":"Guillermo Gervasini, Maria J Caballero, Juan A Carrillo, Julio Benitez","doi":"10.1155/2013/792456","DOIUrl":"https://doi.org/10.1155/2013/792456","url":null,"abstract":"The goal of this study was to assess in human liver microsomes the inhibitory capacity of commonly used antipsychotics on the most prominent CYP450 drug metabolizing enzymes (CYP1A2, CYP2C9, CYP2D6, and CYP3A). Chlorpromazine was the only antipsychotic that inhibited CYP1A2 activity (IC50 = 9.5 μ M), whilst levomepromazine, chlorpromazine, and thioridazine significantly decreased CYP2D6-mediated formation of 1'-hydroxybufuralol (IC50 range, 3.5-25.5 μ M). Olanzapine inhibited CYP3A-catalyzed production of 1', and 4'-hydroxymidazolam (IC50 = 14.65 and 42.20 μ M, resp.). In contrast, risperidone (IC50 = 20.7 μ M) and levomepromazine (IC50 = 30 μ M) showed selectivity towards the inhibition of midazolam 1'-hydroxylation reaction, and haloperidol did so towards 4'-hydroxylation (IC50 of 2.76 μ M). Thioridazine displayed a Ki of 1.75 μ M and an inhibitory potency of 1.57 on CYP2D6, suggesting a potential to induce in vivo interactions. However, with this exception, and given the observed Ki values, the potential of the assayed antipsychotics to produce clinically significant inhibitions of CYP450 isoforms in vivo seems limited.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2013 ","pages":"792456"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/792456","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31296160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 15

Amelioration of collagen-induced arthritis in female dark agouti rats by glucosamine treatment. 葡萄糖胺对雌性黑鼠胶原诱导关节炎的改善作用。

ISRN Pharmacology Pub Date : 2013-01-01 Epub Date: 2013-02-14 DOI: 10.1155/2013/562905

Nagaraja Haleagrahara, Dulanthi Tudawe, Srikumar Chakravarthi, Ammu Kutty Radhakrishnan

{"title":"Amelioration of collagen-induced arthritis in female dark agouti rats by glucosamine treatment.","authors":"Nagaraja Haleagrahara, Dulanthi Tudawe, Srikumar Chakravarthi, Ammu Kutty Radhakrishnan","doi":"10.1155/2013/562905","DOIUrl":"https://doi.org/10.1155/2013/562905","url":null,"abstract":"The present study assessed the therapeutic efficacy of glucosamine hydrochloride against collagen-induced arthritis in female Dark Agouti rats (DA). Arthritis was induced by intradermaly injecting a collagen and complete Freund's adjuvant suspension at multiple sites in the rat at a dose of 4 mg/kg of body weight and thereafter followed by two more boosters of the same dose, after the 1st week and 2nd week of primary immunization. After 21 days from the day of primary immunization, the arthritic group rats were given oral supplementation of glucosamine hydrochloride at a dose of 300 mg/kg of body weight until day 45. The arthritic group treated with glucosamine hydrochloride from day 21 to day 45 showed significant reduction in arthritic histopathological changes of the joints, reduction in paw thickness and also a significant decrease in C-reactive protein and TNF-alpha in the serum. Treatment with 300 mg/kg of glucosamine hydrochloride was able to reverse the arthritic changes, hence suggesting that glucosamine has a therapeutic effect against collagen-induced arthritis.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2013 ","pages":"562905"},"PeriodicalIF":0.0,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/562905","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31296159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 8

Erratum to “Bedtime Single-Dose Prednisolone in Clinically Stable Rheumatoid Arthritis Patients" “临床稳定型类风湿关节炎患者睡前单剂量强的松龙”的勘误

ISRN Pharmacology Pub Date : 2012-09-23 DOI: 10.5402/2012/521976

M. Owlia, Golbarg Mehrpoor, Moneyreh Modares Mosadegh

引用次数: 0

Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats. 罗格列酮(一种PPAR-γ激动剂)短期治疗可改善非肥胖瘦Wistar大鼠的代谢谱和血管功能。

ISRN Pharmacology Pub Date : 2012-01-01 Epub Date: 2012-08-21 DOI: 10.5402/2012/130347

Mohammad M Naderali, Imose Itua, Abdul-Razak Abubakari, Ebrahim K Naderali

{"title":"Short-Term Therapy with Rosiglitazone, a PPAR-γ Agonist, Improves Metabolic Profile and Vascular Function in Nonobese Lean Wistar Rats.","authors":"Mohammad M Naderali, Imose Itua, Abdul-Razak Abubakari, Ebrahim K Naderali","doi":"10.5402/2012/130347","DOIUrl":"https://doi.org/10.5402/2012/130347","url":null,"abstract":"A number of preclinical and clinical studies have reported blood-pressure-lowering benefits of thiazolidinediones in diabetic subjects and animal models of diabetes. This study was designed to further elucidate vascular effects of rosiglitazone, on healthy nonobese, lean animals. Adult male Wistar rats were randomized and assigned to control and rosiglitazone-treated groups and were dosed daily with either vehicle or rosiglitazone (10 mg kg(-1) day(-1)) by oral gavage for 5 days. Compared with control group, rosiglitazone treatment significantly reduced plasma levels of triglycerides (>240%) and nonesterified free fatty acids (>268%) (both, P < 0.001). There were no changes in vascular contractility to KCl or noradrenaline between two groups. However, rosiglitazone therapy improved carbamylcholine-induced vasorelaxation (93 ± 3 % versus control 78 ± 2, P < 0.01) an effect which was abolished by L-NAME. There was no difference in sodium nitroprusside-induced vasorelaxation between the control and rosiglitazone-treated animals. These results indicate that short-term rosiglitazone therapy improves both metabolic profile and vascular function in lean rats. The vascular effect of rosiglitazone appears to be mediated by alteration in NO production possibly by activation of endothelial PPARγ. This increased NO production together with improved lipid profile may explain mechanism(s) of blood-pressure-lowering effects of thiazolidinediones on both human and experimental animals.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2012 ","pages":"130347"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/130347","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30889494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Pharmacological Evaluation and Docking Studies of 3-Thiadiazolyl- and Thioxo-1,2,4-triazolylcoumarin Derivatives as Cholinesterase Inhibitors. 3-噻二唑基和硫氧-1,2,4-三唑基香豆素衍生物胆碱酯酶抑制剂的药理评价及对接研究。

ISRN Pharmacology Pub Date : 2012-01-01 Epub Date: 2012-08-16 DOI: 10.5402/2012/707932

Ahsan Raza, Aamer Saeed, Aliya Ibrar, Muhammad Muddassar, Aftab Ahmed Khan, Jamshed Iqbal

{"title":"Pharmacological Evaluation and Docking Studies of 3-Thiadiazolyl- and Thioxo-1,2,4-triazolylcoumarin Derivatives as Cholinesterase Inhibitors.","authors":"Ahsan Raza, Aamer Saeed, Aliya Ibrar, Muhammad Muddassar, Aftab Ahmed Khan, Jamshed Iqbal","doi":"10.5402/2012/707932","DOIUrl":"https://doi.org/10.5402/2012/707932","url":null,"abstract":"Inhibition of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) is considered a promising strategy for the treatment of Alzheimer's disease (AD). This research project aims to provide a comprehensive knowledge of newly synthesized coumarin analogues with anti-AD potential. In the present work a series of 3-thiadiazolyl- and thioxo-1,2,4-triazolylcoumarins derivatives were designed, synthesized, and tested as potent inhibitors of cholinesterases. These compounds were assayed against AChE from electrophorus electricus and rabbit; and BChE from horse serum and rabbit by Ellman's method using neostigmine methylsulphate and donepezil as reference drugs. Some of the assayed compounds proved to be potent inhibitors of AChE and BChE with K(i) values in the micromolar range. 4b was found to be the most active compound with K(i) value 0.028 ± 0.002 μM and higher selectivity for AChE/BChE. The ability of 4b to interact with AChE was further confirmed through computational studies, in which a primary binding was proved to occur at the active gorge site, and a secondary binding was revealed at the peripheral anionic site. Structure activity relationships of prepared compounds were also discussed.","PeriodicalId":14662,"journal":{"name":"ISRN Pharmacology","volume":"2012 ","pages":"707932"},"PeriodicalIF":0.0,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.5402/2012/707932","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30896031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14